AssetMark Inc’s Insmed INSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.72M Buy
34,871
+613
+2% +$74.2K 0.01% 811
2026
Q1
$5.6M Sell
34,258
-5,474
-14% -$842K 0.01% 636
2025
Q4
$6.91M Buy
39,732
+4,438
+13% +$810K 0.01% 583
2025
Q3
$5.08M Buy
35,294
+3,169
+10% +$388K 0.01% 622
2025
Q2
$3.23M Buy
32,125
+5,892
+22% +$451K 0.01% 679
2025
Q1
$2M Sell
26,233
-111
-0.4% -$8.49K 0.01% 724
2024
Q4
$1.82M Buy
26,344
+291
+1% +$21K ﹤0.01% 732
2024
Q3
$1.9M Buy
26,053
+2,975
+13% +$220K 0.01% 661
2024
Q2
$1.55M Buy
23,078
+17,657
+326% +$685K ﹤0.01% 675
2024
Q1
$147K Sell
5,421
-494
-8% -$13.8K ﹤0.01% 997
2023
Q4
$183K Buy
5,915
+1,116
+23% +$28.9K ﹤0.01% 930
2023
Q3
$121K Buy
4,799
+463
+11% +$10.6K ﹤0.01% 952
2023
Q2
$91.5K Buy
4,336
+709
+20% +$13.5K ﹤0.01% 965
2023
Q1
$61.8K Buy
3,627
+1,091
+43% +$21.2K ﹤0.01% 981
2022
Q4
$50.7K Buy
2,536
+1,330
+110% +$25.7K ﹤0.01% 1035
2022
Q3
$26K Buy
1,206
+335
+38% +$8.03K ﹤0.01% 1085
2022
Q2
$17K Buy
871
+485
+126% +$10.2K ﹤0.01% 1151
2022
Q1
$9K Buy
+386
New +$8.97K ﹤0.01% 1205

Other funds holding INSM

AssetMark Inc's INSM Position: Q2 2026 in Review

AssetMark Inc increased its Insmed (INSM) stake by 1.8% in Q2 2026, buying an estimated $74.2K and bringing the position to 34,871 shares worth $3.72M. The position accounts for 0.01% of the portfolio, ranked #811.

AssetMark Inc first reported a position in INSM in Q1 2022 and has held it in 18 quarters since. The position peaked at $6.91M in Q4 2025. 180 funds tracked by Wall St. Rank hold INSM as of Q2 2026.

  • AssetMark Inc held 34,871 shares of Insmed worth $3.72M as of Q2 2026.
  • AssetMark Inc bought 613 Insmed shares in Q2 2026, an estimated $74.2K.
  • Insmed made up 0.01% of AssetMark Inc's portfolio in Q2 2026, its #811 holding.
  • AssetMark Inc first reported a position in Insmed in Q1 2022 and has held it in 18 quarters since.
  • AssetMark Inc's Insmed position peaked at $6.91M in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Insmed as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.